Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

November 12, 2024

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 81 min

Earnings Call Speaker Segments

Jost Reinhard

executive
#1

Good afternoon, everyone, and good morning as well, and thanks for joining the call covering the third quarter of 2024. Bill is going to open up our presentation today, sharing how he sees business development so far this year and the progress achieved toward our strategic objectives. After that, Wolfgang will give a summary of how we performed financially in the third quarter, talk through the full-year outlook for this year, and lay out the key trends for 2025. We have also invited our divisional heads today to present detailed insights into the growth dynamics and future outlook of their respective businesses. And as usual, a Q&A session will follow the presentations. Before we begin, I'd like to point out the cautionary language in our Safe Harbor Statement. And with that, Bill, over to you.

Bill Anderson

executive
#2

Thank you, Jost, and thank you all for being with us today. As Jost mentioned, the three presidents of our divisions are here alongside Wolfgang and myself, and we’ll be talking about what’s currently happening in their businesses, both at present and looking toward 2025. What I believe you’ll take away from our remarks is enthusiasm regarding the opportunities that lie in front of us, balanced with a clear-eyed view of certain headwinds and crosswinds we must steer through. That is the tone we intend to set with you in March, and it mirrors how we are guiding our businesses. In certain areas we are seeing substantial progress. In pharma, we have enjoyed a solid stretch of favorable readouts. Momentum behind our launch assets is strong, and the early results from the new model look excellent. While we are seeing this considerable progress in some areas, other areas genuinely need more focus. Two illustrations are regulatory hurdles and generic pricing pressure within our crop protection business. Whether or not these matters sit entirely within our control, we must handle them using the resources and make the decisions that do fall within our control. That is simply part of running a business—things you have to steer through: unexpected turns that appear along the way, which require you to adapt. And adapting is fine, provided you remain on the correct path.

Bill Anderson

executive
#3

We feel strongly that the path we've set for this company is the correct one, and we plan to remain on it. Let me begin by discussing how we've performed so far in 2024 and our outlook for the full group. Across the group, we will meet nearly every parameter we set out for 2024. Our expectation is that the agriculture market will be down roughly 2% this year. With that in mind, achieving those figures is quite an accomplishment. So far this year, Pharmaceuticals is growing, tracking in line with the guidance we raised last quarter. In fact, we are confident we will land at the top end of that raised guidance for both sales and earnings. Consumer Health is expanding, albeit more slowly than we anticipated, due to a slowdown in certain markets, especially the U.S. and China. Even so, our results in Pharmaceuticals and Consumer Health are helping to offset some of the softness in Crop Science. Clean EBITDA will land lower because of the headwinds I referenced. That said, as a group we are completely dedicated to achieving our full-year targets for sales growth, core earnings per share, and free cash flow. Let's now review our performance business by business. In Crop Science, we will finish below our guidance for 2024.

Bill Anderson

executive
#4

LATAM represents a major business for us, and we anticipated significant contributions from that region during the second half of the year, comparable to the prior year's performance. Corn acreage in Argentina and Brazil has declined due to weather difficulties and disease pressure. Combined with weak commodity prices and pricing pressure on generic crop protection, this caused us to reduce our 2024 targets. You've observed comparable dynamics throughout the whole industry, and Rodrigo and his team have demonstrated that we can compete and withstand market pressures owing to our innovation advantage, yet in the end, those pressures still affect us. Even so, we must take ownership of this year's results. There are certainly areas where we can improve as we move forward. Regarding 2025, we remain cautious about the market environment. In addition, we face substantial regulatory pressure. Rodrigo will cover more on that during his portion. He will also emphasize our efforts to tackle market pressures and get ready for industry-leading innovation launches in 2027 and beyond. Therefore, from now until that point, it falls to us to compete, regardless of what the market or regulatory situation looks like. And many elements are within our control: optimizing our P&L, bringing innovation to market, managing costs.

Bill Anderson

executive
#5

We've had to work some muscles this year. Those will serve us well moving forward, and I believe we can make them stronger. Our pipeline is great, our portfolio is great, and our people are wonderful. So delivering is up to us. On the Pharmaceuticals side, we raised our guidance last quarter. There are two months left, and we're confident we'll land at the upper end of that guidance. What we're seeing from our launch products makes us happy. Nubeca has picked up pace this year. Kerendia is also growing excellently. That matters because we can expect the Xarelto loss of exclusivity impact to accelerate in the opposite direction. Margin erosion comes along with that. But our focus is on what's within our control: moving assets through the pipeline and delivering successful launches. With Acoramidis and Elinzanetant, we expect the next two to arrive in 2025, and we have strong momentum in renewing the pipeline, in renewing the top line — sorry — in reinvigorating the pipeline and building the base for continued profitable growth down the road. Stefan will share more on that with you. In consumer health, you've become accustomed to steady growth from us over the last five years. Julio and the team fully intend to keep that going while recalibrating growth back toward volumes.

Bill Anderson

executive
#6

Alongside that comes a realignment of where we put our investment dollars across the brands. Resources are being moved toward the brands and markets that matter most, and at the same time we're tackling the main items pressing on our costs and our cash. Our dermatology and digestive health categories keep growing, and that's in large part because of this approach. Our team is now taking it across the remainder of the portfolio, and we expect that to drive growth in 2025. Moving to strategic progress, beginning with innovation. Over the last few quarters I've pointed to where we are with Preceon Smart Corn. The biotech version comes to market in 2027, and the breeding version is already launched in three countries. In September, I saw it firsthand. I walked a field alongside Jerry, a fourth-generation farmer in Northeast Iowa. He planted Preceon at a much higher density than his tall corn. That crop held up against heavy winds in July, reaching up to 70 mi per hour. His neighbors were left dealing with broken crops and dramatically lower yields, yet his corn stood tall. Or I suppose short is the better word. Well, in the end, the crop gave him the best performance he's ever seen on that field: 258 bushels per acre.

Bill Anderson

executive
#7

A bit earlier, I brought up some of the difficulties we're seeing in agriculture. So for farmers who are looking for differentiated value from us, innovation of this kind matters even more. Over in pharmaceuticals, Nubeca passed the blockbuster mark in September and has built market-leading positions in the indications it currently serves. This growth has been given a real boost by our new model. Choices on how sales territories get covered and how resources get allocated are now largely made by the people doing the work, rather than being pushed up and down the hierarchy. What that means is more time spent with physicians and patients, quicker and more sharply focused work on items such as filing dossiers and NDAs, and faster growth. In consumer health, the teams on the ground tell me they are nearly halving launch times, especially in our nutritional supplement business. We will keep on shortening the gap between a consumer insight and reaching the market and meeting a need. Moving now to litigation. We hold firm to our commitment to containing this issue across the next two years. There will be a continuing flow of news on trials, on our legislative efforts, and on speculation regarding other potential measures. As I have said before, we are exploring every avenue available to contain the issue, but we will comment on those plans only when doing so serves the company's interest.

Bill Anderson

executive
#8

When it comes to the glyphosate litigation, we'll now choose which case we take to the U.S. Supreme Court for review. Should the court agree to hear it, our hope is a ruling during the 2025 to 2026 session. Beyond the courtroom, I'm seeing momentum build among politicians, farmers, and other stakeholders who insist American farmers deserve legislative certainty. On top of that, companies such as ours are pushing back against the nebulous funding that frequently bankrolls the U.S. litigation industry. We recently stood with more than 100 major companies spanning industries to ask the courts to require disclosure of third-party financing in lawsuits. Regarding PCBs, we're also anticipating an important decision in the months ahead — this one from the Supreme Court in the state of Washington, on the Erickson case. Taken together, plenty of work remains on the litigation front. This is a long road, and there's no quick fix. Our focus is on the bigger picture, and we're pursuing multiple avenues. We'll know more about the Supreme Court in 2025, and we'll keep working to significantly contain the risks. Wolfgang will now cover cash in his update, but as I said at the outset, we're fully on track for the year.

Bill Anderson

executive
#9

Turning lastly to dynamic shared ownership — I first walked you through this new operating model on our Q3 call last year. Back then, we were only at the start of the journey. Roughly 2,500 people had been brought into the system. As of today, it extends across the vast majority of the organization. The results are bringing substantial change. Since the start of the year, the company has 5,500 fewer jobs, and managerial roles make up a significant majority of those. Above all, the way we run the business is improving. Not long ago I went to Garbagnate, which is a production site outside Milan for our pharma division. A cross-functional team was set up there to try to take 10% off the batch release time, which ran approximately two to three weeks. They operated in three 90-day cycles. Decisions could be made on the spot by them, and factory floor operators sat on the team. At this point, release time has been cut by almost 50%, with tangible benefits for inventory, waste reduction, and cash flow. Mission impact for our people, quicker innovation for patients, and better cash conversion for you. That is what we're going after.

Bill Anderson

executive
#10

Clearly, much more remains for us to do when it comes to scaling this effort. Implementation is at a critical stage at the moment. So, as a management team, we are keeping our focus firmly on the ball. We are making sure this overhaul does not end up like more traditional restructurings, which are usually ineffective. Initially, when I would ask about some success stories, I kept hearing the same two or three examples, and then we would get a new one each month. Now I am hearing stories like the ones I gave you, essentially every day. I am confident that will translate into results for you and a bright future for our customers and for us. So before I hand things over to Wolfgang, I would just like to say that I am very happy he is extending his contract. He had originally planned to retire after his contract expired next year, but he will stay on board for one additional year to see through the three-year journey. Wolfgang, you have been a great partner to me, and I am really happy you are staying on board. So thank you for your attention, and over to you, Wolfgang.

Wolfgang Nickl

executive
#11

Thank you, Bill. Before I move on to our full-year outlook and the vectors we expect to see as we head into next year, 2025, I want to spend a moment on the Q3 results. As usual, any comments on sales growth are on a currency- and portfolio-adjusted basis. In Q3, group sales rose modestly, up 1% compared with the prior year, as growth in pharma and consumer health more than offset a decline in crop science. EBITDA before special items reached €1.3 billion, which is 26%, or roughly €430 million, under the prior-year quarter. That gap is mainly due to weaker pharma and region results. Foreign exchange is still a significant drag this year, with an almost €440 million headwind to our top line in Q3 and around €1.2 billion year to date. On the bottom line, FX produces a negative impact of 40 basis points on the group margin in Q3 and also year to date. The effects on divisional margins vary considerably, driven largely by differences in the geographic distribution of sales and in the cost base. Consistent with the performance and outlook of each business, we anticipate lower expenses from short-term incentive provisions for crop science and consumer health, while for pharmaceuticals we see the reverse, with provisions up versus the prior year.

Wolfgang Nickl

executive
#12

Core earnings per share in Q3 were $0.24, which is $0.14 lower than a year earlier. Weaker contributions from EBITDA before special items were partially offset by an improved core financial result. Our core tax rate for Q3 was 46%, and that reflects a revaluation of deferred tax assets in the United States, which was set off by an impairment in crop science during the quarter. As you can see in the appendix, reported earnings per share were EUR -4.26. The gap versus core earnings per share comes mostly from non-cash relevant impairment losses of roughly €3.8 billion recorded in our crop science division. The main factors are weaker business prospects, particularly in crop protection, FX, and the dicamba label uncertainty. Weighted average cost of capital, by contrast, were favorable. Free cash flow was €1.1 billion, versus €1.6 billion in last year's third quarter, largely because of the quarterly timing of customer payments in crop science. Year to date, free cash flow stands at €-200 million. That compares with €-2.9 billion for the first nine months of the prior year. The difference is mainly due to lower incentive payouts and lower settlements. We expect strong cash contributions in Q4 so we can deliver on our full-year commitments.

Wolfgang Nickl

executive
#13

By the close of Q3, net financial debt had come down to €35 billion, helped by the quarter's positive cash contribution and an FX tailwind of roughly €600 million. Now let's turn to how each of the divisions performed. In Crop Science, the third quarter is seasonally our smallest when it comes to sales and earnings. Latin America, which was the strongest contributor in Q3, has faced considerable weather challenges as well as pressure from stunt disease. As Bill mentioned, this materially cut corn acreage in Argentina and Brazil alike, and that was compounded by extended softness in commodity prices and generic pressure on crop protection pricing. Glyphosate-based herbicides fell 19% as shipping patterns normalized as expected. That produces an overall sales decline of 4%, with sales coming in at about €4 billion. Our core business came in flat in Q3. LATAM weakness was offset slightly by strong volume in our core crop protection products, despite ongoing pricing pressure in the industry. On the profitability side, EBITDA before special items came in at EUR 35 million, being in absolute terms roughly EUR 60 million above prior year's quarter. Main drivers were the already mentioned adjustment to the short-term incentive provision, lower COGS, accelerated DSO efficiencies, and a favorable FX effect on the margin.

Wolfgang Nickl

executive
#14

Moving on now to pharma. In Q3, sales rose 2% year on year, reaching EUR 4.5 billion, driven primarily by the strong performance of our launch assets and Eylea. Nubeca, with growth of 83%, has now achieved blockbuster status, delivering almost EUR 1.1 billion in sales during the first nine months of this year. For Kerendia, we nearly doubled sales versus last year's Q3. Eylea posted a 9% sales increase compared with the prior year, with growth across the majority of our marketed territories. By contrast, and consistent with what we guided, Xarelto faced accelerating generic headwinds during the third quarter. Quarterly sales fell 23% year on year, which led to an 11% decline year to date — in line with our guidance of a double-digit sales decline. Third-quarter sales were affected by a nearly complete genericization in Canada, along with rising generic pressure in the U.K. Following the recent ruling by the highest patent court declaring the once-daily patent invalid, we expect U.K. sales to degrade irreversibly through year-end. Beyond that, we are seeing increasing at-risk launch dynamics of generics across many European countries, led by France. As you would expect, we are taking vigorous action in court to defend our IP rights.

Wolfgang Nickl

executive
#15

On profitability, EBITDA before special items reached € 1.1 billion, with a margin of 24.4%. The big drop compared with last year comes from the short-term incentive provisions I mentioned earlier, plus an unfavorable currency impact of roughly € 134 million. On top of that, we have continued gross investments in our launch products, though we managed to offset the product mix shifts described, which stemmed from lower Xarelto sales, through disciplined OpEx management and favorable pricing. Our Consumer Health division posted 6% sales growth year over year in the third quarter, with revenues of € 1.4 billion. That growth was broad-based across every category, although regional dynamics differed. In EMEA, we saw substantially higher sales of cough and cold products as the cold season began, mainly on higher volumes, particularly for the Aspirin product family. Latin America sales also increased, driven chiefly by strong results in nutritionals as well as pain and cardio. That said, we did encounter some headwinds. A sluggish start to the cold season in the United States resulted in retailer orders below expectations. In China, markedly softer household consumption weighed on our prevention-focused categories, including nutritionals and digestive health.

Wolfgang Nickl

executive
#16

On top of that, we saw the impact of shutting down Care/of, our direct-to-consumer nutritional supplements operation in the United States. Even with those headwinds, our Q3 clean EBITDA margin came in at 25.5%, which is 330 basis points better than a year earlier. The main drivers behind that gain were higher sales, reduced incentive provisions, and favorable foreign exchange effects on the margin. We stay committed to managing costs effectively while still investing enough in our innovative brands and product launches. Let's turn now to the divisional guidance for 2024. In crop science, we now project sales to fall between -3% and -1% on a currency- and portfolio-adjusted basis. That reflects a revised outlook for our core business, hit by the challenges in LATAM as well as mounting generic pricing pressure on crop protection. Our margin outlook is affected as well. EBITDA margin before special items is now projected at 18% to 20% at constant currencies. In pharmaceuticals, we confirm the full-year guidance at constant currencies that we raised following the second quarter. That said, we now expect to land toward the higher end of the sales and margin guidance ranges. In consumer health, we expect moderately lower market growth through the remainder of 2024.

Wolfgang Nickl

executive
#17

The main reason here is that economic conditions have softened in certain markets. In the U.S., consumers are getting more cost-conscious, and we're seeing early signals that the cough and cold season is weaker than expected. In China, market growth is slowing down. When we look at Q4, we expect retailers to keep optimizing their working capital, thanks to better supply chains and product availability. Looking at the full year, this impacts our ex-factory net sales, though our sell-out performance is still in line with market trends. Taking all of this into account, we now project sales growth for 2024 of between 1% and 3% on a currency and portfolio-adjusted basis. With a clear focus on our operational efficiency programs and targeted price management, we still expect our EBITDA margin to land within the corridor we previously guided. At group level, we are fully committed to hitting our sales growth, core EPS, free cash flow, and net financial debt targets for the year, and all of this is at constant currencies. Given the updated divisional outlook, we are lowering the clean EBITDA outlook to -11% to -8% compared to previous year. We now expect a better core financial result of approximately €2 billion versus approximately €2.3 billion previously. This also aligns with the actual year-to-date performance.

Wolfgang Nickl

executive
#18

In addition, we needed to revise our core tax rate for the entire year to 24%-25%, compared with roughly 23% before. That change stems from a revaluation of deferred tax assets in the U.S., which the impairment in crop science during Q3 that we mentioned earlier had set off. We have also refreshed our FX assumptions using September rates and spot rates. Our sales are now projected to face a bigger FX headwind, at -3% to -4%. For net debt, the picture is reversed: we now assume no material FX impact, where earlier we had assumed a €500 million increasing effect. Let me also take this chance to recap the key business vectors for next year. My divisional colleagues will provide further detail on these in their sections. In pharmaceuticals, we foresee continued strong growth momentum from our launch brands. At the same time, we expect generic headwinds for Xarelto to intensify, which puts added margin pressure relative to 2024. In crop science, we remain cautious about the ag market outlook and expect muted growth. Beyond that, we anticipate regulatory challenges in our crop protection business, which will bring greater pressure on profitability. In consumer health, we expect market growth at a level similar to this year.

Wolfgang Nickl

executive
#19

Given that market, we anticipate delivering strong growth, with volume as our main focus. Under our present assumptions, FX will probably continue to be a significant headwind. On the whole, we foresee a subdued picture for both top and bottom line in the coming year, with earnings likely to decline. We intend to speed up our cost and efficiency initiatives to partially offset that, and we'll stay sharply focused on cash conversion. Although we plan to offer a certain degree of transparency regarding the key drivers for next year, our planning discussions are still underway at present. We'll give specific 2025 guidance alongside our full-year results. With that said, I'd like to pass things over to my colleague Stefan for pharma.

Stefan Oelrich

executive
#20

Thank you, Wolfgang. Within our pharmaceutical business, we keep demonstrating meaningful headway against our strategic plan. We remain positioned to hit the higher end of both our revenue and earnings guidance for the entire year, and at the same time we have added further value to our mid- and late-stage pipeline. Thanks to extra phase 3 results shared during the third quarter, the already strong clinical profiles of our late-stage assets — Nubeca, Kerendia, and Elinzanetant — have been further enhanced, reinforcing the best-in-class or first-in-class aspiration for each of these three medicines. The ARANOTE findings presented at ESMO in September showed a meaningful gain in radiological progression-free survival among patients with metastatic hormone-sensitive prostate cancer, and confirmed once more the tolerability profile Nubeca has already established. These results lend further backing to how Nubeca is positioned and to filings for a third indication in both the United States and Europe, which have already been submitted. Moving to Kerendia, the FINEARTS-HF and FINE-HEART studies, presented at ESC in August, revealed significant and consistent gains in CV outcomes for heart failure patients whose left ventricular ejection fraction is equal to or above 40%, irrespective of baseline therapy. No other mineralocorticoid receptor has demonstrated this previously in this area of high unmet medical need. For Elinzanetant, the OASIS-3 trial gives us additional consistent efficacy and sustained safety data across 52 weeks.

Stefan Oelrich

executive
#21

This information further supports the best-in-class potential we hold for a non-hormonal therapy addressing moderate to severe vasomotor symptoms. Following our submissions to the U.S. FDA in August, we recently filed for marketing authorization in the E.U. Right now we are stepping up pre-launch activities, drawing on our global number one position in women's health and our strong presence in key countries like the U.S., where a launch is expected by mid-2025. Turning to replenishing our mid- and late-stage pipeline, that work is also underway. In line with our commitment to precise and personalized healthcare solutions in disease areas with the highest unmet needs, during the third quarter we enrolled the first patient in our phase 3 SOHO study, which uses a HER2 TKI in HER2 mutant non-small cell lung cancer. Thanks to the PHOTON data, the profile of Eylea 8 mg has been further strengthened, and the ATTRibute-CM data showed a potential best-in-class profile for Acoramidis in ATTR cardiomyopathy, which we look forward to launching in Europe next year. We have additionally moved our first gene therapy, AB-1005, for treating Parkinson's, into Phase 2, along with our cardiovascular drug candidates, anti-alpha-2-antiplasmin and the oral sGC activator. For 2025, we anticipate continued growth momentum from Nubeca and Kerendia.

Stefan Oelrich

executive
#22

With Eylea's 8 mg formulation — and a prefilled syringe has just become available for that in the first markets too — we're in a strong position to protect our market-leading position, and our base business should stay robust. We're also looking forward to the upcoming launches of Acoramidis and Elinzanetant, expected in the first half and second half of the year, respectively. Next year, we'll also demonstrate further R&D progress with Bemdaneprocel in Parkinson's as it moves into the next development stage, based on the positive 24-month data recently announced, and we're expecting additional data readouts, on which we'll update you separately as that data comes in. On the other hand, we must also acknowledge that a further expected decline in Xarelto, along with ongoing growth investments into R&D and launches, are likely to dilute margins. Overall, the division's sales trajectory across the next two years will be significantly affected by the genericization dynamics of Xarelto. While we believe we'll be able to largely offset expected declines through our continued growth momentum from our key launch products, the key question is when exactly genericization will peak. As such, 2025 or 2026 may prove to be a transition year for Bayer Pharmaceuticals, but we are set to return immediately to growth again after that.

Stefan Oelrich

executive
#23

Since our DSO transformation is now operating at full speed, we are already observing quite strong outcomes from putting our new operating model to work — Bill touched on this during his remarks. Thanks to the outstanding efforts of roughly 300 product and customer teams, we have grown considerably leaner as an organization while sharpening our attention on patients. Within R&D, we have established the groundwork for a sturdier innovation model, with sharper focus, better quality, and greater productivity across all of our research and development work. Given this resource reallocation and tighter focus, we are well positioned to keep strengthening bottom-line resilience and are ready to tackle the challenges and, naturally, make the most of the opportunities that lie ahead. With that said, Rodrigo, the floor is yours, in St. Louis.

Rodrigo Santos

executive
#24

Okay, thanks Stefan. It's good to hear from you. During our Capital Markets Day, we stressed that our emphasis on innovation and putting farmers first will keep shaping agriculture across the coming 10 years, with performance above the market. That's what we expect for this year, adjusted for today's pressures and volatility. The drivers are well known throughout the industry. We have weather challenges, lower commodity price levels, and generic pressure in crop protection. That began in Europe and North America during the first half of the year and has now carried into Latin America in Q3, where a material acreage reduction in corn in Argentina and in Brazil has compounded it, as Bill and Wolfgang mentioned. Soybean pressure in Brazil has also sped up alongside the lower commodity prices. These are profitable businesses in which we hold a very strong position, and we plan to deliver much of our growth for the second half of the year. Consequently, we have now adjusted our Crop Science 2024 guidance, something we did not take lightly, and we moved quickly to accelerate DSO savings and execute operational efficiency in COGS and OPEX, and to help offset the margin impact from sales effects. Although we see challenges in the ag market, our global leadership in corn and soy has enabled us to deliver resilient performance.

Rodrigo Santos

executive
#25

Looking at year-to-date, our core business once again beat the industry-weighted average, and that's even after a strong performance in the prior year, which you saw on this slide. As we look at 2025, we anticipate soft commodity prices lasting a long time, and those will keep weighing on on-farm profitability, while generic pricing pressure in crop protection is going to stay with us. With the Latin market recovering and crop protection volume improving, we'd expect only modest growth in the ag market next year. During 2025, our business will in all likelihood feel the effects of difficult regulatory developments, including the loss of registration for Movento in Europe and issues surrounding our dicamba label in the US, which the FDA is still reviewing. A vital crop protection tool such as dicamba not being available for farmers' weed management is a pain for us, but it's even more of a pain for the farmers themselves. We're continuing to work at engaging the FDA, industry partners, and grower groups to build support for label approval. That said, given where the FDA currently stands, there's a risk we won't have an approved label for the 2025 season, and that could also have implications for our soy and corn seed traits and licensing. Farmers buy our products because of superior yield, agronomics, and the service behind what we offer, and they should feel confident that strong soybean and cotton crop protection combinations are available in the market for weed control.

Rodrigo Santos

executive
#26

We're putting several measures in place so farmers have an integrated wheat management program they can rely on, giving them confidence when making purchase decisions for a successful 2025 season. A material effect on our top and bottom line could come from these two regulatory challenges. Because of the influence on the global license business and the mixed effect of sales in high-margin regions, the impact on EBITDA margin could fall in the range of 200 to 300 basis points. With these dynamics in mind, we are speeding up our strategic agenda to tackle market pressure and get ready for our upcoming blockbuster launches. Our cross-functional DSO teams will enable these actions. With about 80% of our organization activated, these teams are on the ground and empowered to drive five critical initiatives. First, we feel very strong about our corn franchise and will drive continued growth and industry leadership, since we have seen leading growth CAGR of more than 7% over the last four years. Overall, corn market dynamics are intact, and we are on the front side of game-changing launches with our Preceon Smart Corn System in multiple regions, as you heard from Bill. Second, we are facing headwinds in soy as we work to regain a label for dicamba.

Rodrigo Santos

executive
#27

In addition to the work we're doing to engage with the EPA, we'll keep defending our global position by delivering elite germplasm in North America, while holding on to our trade leadership position in Latin America. With the next generation of soybean trait launches set to begin in 2027, we have the potential to reset industry standards for weed and insect control, which would give our seed and crop protection portfolios a springboard. Third, crop protection markets have been hit by channel fill, generic pricing pressure, and regulatory challenges. To remain competitive with our leading position in the industry, we're reviewing our crop protection strategy so we can optimize our franchise value. Fourth, our global platforms are delivered through our industry-leading innovation pipeline. We're making good progress launching our 10 blockbusters over the next 10 years, including both the Preceon and HT4 soybean platforms. We've launched more than 20 biotech traits in 10 years, and now we're literally launching fourth and fifth generation traits, and that innovation isn't only in seeds and traits. Next year, we will launch our new insecticide Plenexos, and we're advancing to stage four of our new herbicide. This innovation engine is poised to deliver the next round of competitive differentiation as we begin to see those waves of launches.

Rodrigo Santos

executive
#28

Fifth, we’re putting more emphasis on stronger cash conversion and optimizing the P&L so we make the most of what we have. That means looking at what it costs us to serve customers, and also reviewing our product portfolio, so we’re putting priority on products with high margins that matter to farmers—ones that make a step-change difference for our customers—while using our tools and capabilities to do that as promptly and effectively as we can. As we laid out in March, we are 100% focused on creating value for our farmer customers and for our owners. We’ve got the portfolio, we’ve got the pipeline, and the people to back it. Where outside pressure is getting in the way, we are committed and confident that we’ll adjust accordingly, and we’ll share more details with the full year results. With that, let me hand it back to you, Julio.

Julio Triana

executive
#29

Thank you. Thanks, Rodrigo. And hello, everybody. Since this is the first time I've had the opportunity to speak with you regarding our Consumer Health business, I'm glad to have the chance to do so. Six months have passed since I joined Consumer Health, and during that period, I've been getting reacquainted with this wonderful business, which consists of wonderful people, trusted brands, and solid fundamentals. Consumer Health is an appealing market. Over decades it has produced steady growth, with strong prospects globally. A balanced portfolio, nicely proportioned across both categories and regions, is an advantage our business enjoys. That broad portfolio has served us well previously, since we've been able to take advantage of shifting demand patterns. However, during the last two years, price has been the main driver of our growth. In an environment with high inflation, that can happen, but over the long term, it isn't healthy. So going forward, we're correcting that by achieving a healthier balance between price and volume mixed growth. That ambition sits at the center of our vision, which is to reach billions of people with the most trusted self-care solutions. So how will we accomplish that? We're relying on three priorities. The first concerns investment focus, particularly at the core of our business.

Julio Triana

executive
#30

Brands such as Bepanthen, Claritin, and Elevit have tremendous equity with consumers and solid scientific support, and that makes them excellent platforms for investment. What we've discovered is that we can be more choiceful with our funding, moving the right resources to the right brand in the right market. That is going to deliver better growth down the road. Second, we stay open to selective expansions in the right segments or markets. Here, I want to highlight our team in India, a market we re-entered only recently, have kept investing in, and where we're seeing excellent results. Finally, our new operating model of Dynamic Shared Ownership opens up so many opportunities in the consumer health space. It lets us be faster, more efficient, and more creative. I had the chance to try similar ways of working at my last station in Japan, which gives me some experience in implementing this model. In Consumer Health, we're already seeing benefits when it comes to speed to market and consumer centricity across many of our operations around the world. That is only going to accelerate going forward. So what does this mean for 2025? Next year, we expect the market to grow at a similar level in 2025 than in 2024.

Julio Triana

executive
#31

With that in mind, our goal is strong growth, centered on volumes. Speed, growth, and efficiency will come from our new operating model, which offsets the inflation effects that are still lingering. To close, these business fundamentals give us confidence. Our vision is to bring self-care to billions of people at a moment when it matters enormously. Great opportunities lie ahead across our portfolio and through our new operating model, and we will lead the effort to build preference for our brands, winning one consumer at a time. Over to you, Bill.

Bill Anderson

executive
#32

Okay, thank you all, and I appreciate everyone tuning in. Overall, my hope is that this gives you a useful picture of where each of our businesses stands right now and what we anticipate as we look toward 2025. So before we open it up to your questions, let me recap. Regarding our 2024 guidance, we will deliver on the figures for sales growth, core EPS, cash flow, and net debt. On the strategic side, progress has been made. The new model has been scaled up quickly. The pharma pipeline has been upgraded at real speed. That said, there's still more work ahead. Litigation uncertainty needs to be contained, and a team is focused on that around the clock. Then there's operational performance, an area where we constantly push to be more competitive. Rodrigo and his team are handling that in crop science. In pharma, two additional significant launches are being readied for next year. Consumer health is putting more targeted resources behind our brands. Across all three businesses, we're getting leaner, more entrepreneurial, and more dynamic. The strategy and the plans we set out in March give us confidence. Our focus is right for our customers, for our company, and for you. Thank you for your attention, and I'll hand things to Jost now for the Q&A.

Jost Reinhard

executive
#33

Thanks a lot for the presentations. We’ll now start the Q&A session. Before we begin, just a few housekeeping notes. If you have questions, please raise your hand and follow the instructions given in the chat. So that as many participants as possible can take part, please keep yourself to two questions. Today’s first question comes from Vincent Andrews at Morgan Stanley. Vincent, can you hear us?

Vincent Andrews

analyst
#34

I can hear you. Can you hear me? Hopefully. Thank you. Good morning, everyone. Rodrigo, I'd like to follow up on what you said about dicamba. There are a few parts to the question. First, when do you think the go-no-go date falls, the point by which you need EPA registration or farmers won't be able to spray dicamba over the top next year? And second, assuming the product isn't re-registered in time for over-the-top application, could you clarify what offering you'll give farmers to compel them to stay with the Bayer seed product next year? Will you be providing bundles of alternative chemistries? Do you think there'll have to be some discounting? I'm just trying to bridge that financial comment you made about the 200 to 300 basis points of sales and margin impact. I want to make sure I understand whether that's just on the chemistry, and how much of that you're already including in terms of potential risk to seed sales. Thank you.

Rodrigo Santos

executive
#35

Thanks, Vincent — that really helps me clear that one up. So I’ll begin by discussing the upcoming season. Naturally, we have a range of scenarios. And early next year, absent the commentary, farmers would struggle to get access for the season. That’s why, under this scenario, we’re looking at what we presented here today. But it’s exactly as you described. We’ve already brought to market plans that give farmers different chemistry options to manage weeds amid the issues we face. That’s also why our book is very well ordered for our Asgrow and Channel brands — our seed. The effect we cited here today, we see as mainly stemming from our licensing, which is why we described top and bottom line as similar, since it comes from our license. On the market in this 2024 season, we confirmed that over 40% of the market was using the Xtend platform. And a high single digit there comes from multinationals using our platform. The impact here mainly originates from that. It’s on the chemistry side too, but chiefly it comes from the licensing business.

Rodrigo Santos

executive
#36

We remain quite confident when it comes to the herbicide side, correct? So we're confident that approval will come through. For the 2026 season, we're taking the view that we'll return to full normality as we planned today, though this is the scenario we have so far. It's very early. We've just got a new administration coming into place in the U.S. At the moment, we're in this transition period right now in the U.S. That's why we set out these scenarios as a vector for next year, because of the licensing. But it's mainly licensing, Vincent, because of our order books in Channel and Asgrow, with the marketing actions you mentioned, the offers we put to the farmers. We have a very strong order book for Asgrow and Channel, as we have. So that's the scenario we planned today. And that's why we're considering this one-time event for 2025. It's a one-year impact that we're considering for our licensing business in extent. Thank you. Great. Thank you, Vincent. Thank you, Rodrigo.

Jost Reinhard

executive
#37

Our next question is from Sachin Jain at Bank of America. Sachin, are you able to hear us?

Sachin Jain

analyst
#38

Hello there. Apologies, I had myself on mute. I trust you can hear me at this point. This is Sachin Jain calling from Bank of America. I appreciate the opportunity to ask my questions. I have a couple of financial ones, Wolfgang and Bill, simply to try to clarify what was said about 2025. I realize we are still awaiting additional guidance, but speaking directionally, I am curious whether you could quantify at a high level how large the decline will be for 2025. Based on the divisional remarks, Crop Science EBITDA might fall in the mid to high single digits. So I simply wanted to verify whether that estimate is roughly right. Then my second question, which you kind of touched on, is this: assuming the first point holds, could you give us some detail on which OpEx or DSO savings you are able to pull forward in order to offset that underlying pressure? That covers my first question. And then a brief question for Stefan. You said you anticipate the Xarelto impact will peak in 2026. That remark left me somewhat puzzled, since the U.S. LOE falls after that date. So I hoped you could clarify that for me. Thank you.

Wolfgang Nickl

executive
#39

Hey, Sachin. Wolfgang here. Let me get us started. As I mentioned during today's call, the intent was more to provide you with some directional vectors, going beyond what Rodrigo covered regarding registration. We aren't in a position right now to put a number on EBITDA. So give us some time to work through our planning. We'll share our guidance — our precise guidance — alongside the annual results. We feel quite good about where we stand on DSO, including from a financial standpoint. We're executing. You heard Bill mention 5,500 positions that no longer exist versus the beginning of the year. That ties to EUR 500 million in savings contributing this year. And you can be sure we'll do everything within our control to speed up our path toward the two billion we talked about at our capital markets day. I also want to reiterate a point from my script. Beyond that, we'll keep a laser focus on everything cash-related — not just improving profitability, but also working capital, CapEx, and so on. That's our fourth priority for bringing net financial debt down. We're in good shape this year — solid free cash flow, solid reduction. But you should expect us to push hard on that too.

Wolfgang Nickl

executive
#40

Stefan, the floor is yours.

Stefan Oelrich

executive
#41

Thanks, Sachin — good catch there. You're clearly right that our 2026 discussion covers everything apart from the contracted U.S. business, and we'll have that business for all of 2026. So, nice catch. Appreciate it.

Rodrigo Santos

executive
#42

All right. It seems Vincent had a follow-up question that we couldn’t hear here in the room. So, Vincent, may I ask you to come back into the chat, and then—

Vincent Andrews

analyst
#43

Thanks, Rodrigo — that’s really nice of you to say. I was actually just about to ask: I didn’t hear you say anything about crop chemical raw material costs being lower next year, or seed production costs coming down next year either. But I believe there’s a general expectation that you ought to get some benefit from that in 2025. If you could say a little about that, it would be helpful.

Rodrigo Santos

executive
#44

Absolutely, Vincent, and you've hit the nail on the head. For the 2025 season, we're putting a number of measures in place, taking into account some of the scenarios. We're observing a decrease in raw material costs. We're also seeing cost reduction on our seeds platform. The DSO savings that Wolfgang mentioned just a moment ago continue to move forward as well. And in crop science, we already have more than 80% accelerating that effort. On top of that, a major transformation is underway within the organization. You've seen plenty of the examples here today. I wish we could share a bit more of what comes out of the visits we conduct with the sites or with the organization, with the customer-facing front lines, because we're also tackling our cost to serve. How can we become more effective with our marketing tools, marketing programs, and numerous other actions? That, however, forms part of the 2025 plan, and as Wolfgang said, we are ready now, working on the measures and the actions we're taking. I simply wanted to give you a bit of insight into some of the regulatory vectors we need to handle for 2025. Thank you, Vincent.

Jost Reinhard

executive
#45

Much appreciated, Vincent. Moving on, our following question is from Joel Jackson at BMO. Joel?

Joel Jackson

analyst
#46

Hello there, can you hear me okay?

Jost Reinhard

executive
#47

Yes, you’re coming through loud and clear.

Joel Jackson

analyst
#48

Can you hear me now? My apologies—that was on our end. Good afternoon, and good morning. I'd like to build on the second question Vincent raised. I'll do my best to phrase this properly. Some of your competitors are placing a lot of emphasis on tailwinds from deflation in seed costs and crop chemicals costs that they expect next year, in line with earnings growth. You, however, are pointing toward lower margins in crop science despite DSO. Could you help us understand why those deflation tailwinds aren't producing growth in crop science? Does glyphosate play a role here? Do seeds play a role? Or is this something else that Bayer is facing in 2025 in crop science and that competitors are not? Thank you.

Rodrigo Santos

executive
#49

Okay, Joel, I’ll take this one — and hopefully without laying out the entire picture for 2025, just a bit of it. We keep seeing expansion across our main core areas, correct? Take seeds and traits as an illustration. Our platform there is really strong. This year delivered yet another solid performance. Look at corn, for instance: globally we’re picking up nearly 1 point of market share in corn this year. Naturally, we’re feeling the effect of 4 million fewer acres in the U.S. Acreage in Europe came down because of the war in Ukraine, and Argentina and Brazil both also have reduced acreage. It’s a highly unusual season for corn, yet our corn results — our new products, our new launches — are generating substantial share gains against the number two player in many important markets. In soybean, we maintain the equilibrium we referenced earlier, and soybean gave us another year of growth. Turning to crop protection, we’re bringing out new formulations, and we’re also pushing cost efficiency, and we expect to see that again in 2025.

Rodrigo Santos

executive
#50

We'll keep building on that within our core business and core platforms. Let me spotlight a few of the vectors today around some key elements. I figured the dicamba question was coming given the season. And naturally, there's also Movento, which I brought up earlier. We're still working through 2025. Yes, 2025 is a specific issue given the regulatory impact. But once again, we stay very confident in our growth platform. And if you'll allow me, let me take this question to touch on the mid-term: what we guided on the mid-term at the capital market day, we're confident on that. We're going to grow above market. We're going to see what we call low- to mid-20s margin — EBITDA margin — that we have for the mid-term. And that's what we're planning. What we're working toward in the mid-term is exactly the same. We're just looking at this one-time event, the regulatory impact for 2025. But the global platform and the key platforms — we continue to drive the growth that we're planning. Joel, thank you.

Joel Jackson

analyst
#51

Alright, and for my second question — it's a difficult one, but I'll go ahead and ask it. I'll do my best to phrase it well, and hopefully you'll be able to answer it as well as you can. With the new U.S. administration and plenty of views suggesting that the people you appoint, or the policy decisions on agriculture, might come from someone who wants to move toward an environment with less GMO, one with fewer crop protection chemicals, perhaps something closer to the regulations we have in various European countries. If that turned out to be the situation — and this is a very broad question — how would Bayer adjust its portfolio, its plans, and its products if you had to shift toward a somewhat different portfolio in the U.S., maybe one that's a bit more like a European ag environment, if that makes any sense? Thank you.

Bill Anderson

executive
#52

Sure, thanks Joel. I’ll take that one. First of all, speculating about who will hold which positions in Washington feels quite premature to me. But one point is very clear: people spoke, and voters sent an unmistakable message about the economy, especially regarding inflation. Food inflation is probably the area cited most often. As background, in 1970, American households spent 11% of their total income on food. By the late teens, a few years ago, that figure had fallen from 11% to 7%. Then, over the last five years, it rose from 7% right back to 11%. That is one reason American consumers have been so unhappy and, frankly, distraught about inflation. Products such as glyphosate are among the main tools we need to help keep food prices affordable. For example, 95% of row crops in the U.S. are now grown with no-till farming using products such as glyphosate. That has a tremendous effect not only on soil quality and on how much fuel farming requires, but also an enormous effect on cost. So I don’t think it is very likely that any policymakers would try to convert U.S.

Bill Anderson

executive
#53

Turning to a sort of European-style farming model — because the reality is that Europe, under the regulations it has now, can't produce enough crops to feed the livestock needed to feed its people. Which explains why Europe continues, to this day, to bring in crops from Brazil, from the U.S., from Argentina. So honestly, I don't believe that's a very difficult question to answer. I'd say we've done quite well cooperating with policymakers on both the Republican and the Democratic side over the years, since everybody shares a common stake in ensuring Americans can afford their food and in ensuring America stays a strong food exporting nation. So I'd say that's probably the sensible way to view it.

Jost Reinhard

executive
#54

Thanks, Bill. Next up from Goldman Sachs is James Quigley. James, the floor is yours.

James Quigley

analyst
#55

Hi there. I hope you can hear me. Thanks for letting me ask a couple of questions. One is about crop, the other about farmer. On the crop side, Rodrigo, you talked about returning to an EBITDA margin in the mid-20s. So what has to occur for us to get back to that level? And you said this is kind of a one-time effect for 2025. But should we look for a sharper bounce back in margin in 2026, or a more gradual recovery from here? One thing that worries investors, I guess, is how to square your confidence in the business with yet another significant impairment that reflects the outlook. So how do those two things fit together? Then, in pharma, Stefan, following up on Sachin's question, what do you now expect regarding the shape of the Xarelto patent expiry? You noted the growing pressure in the U.K. We also have additional at-risk launches, plus the impact in the U.S. So is there any update on how you see that shape playing out, relative to what you presented at the Capital Markets Day a few years ago? Thank you.

Bill Anderson

executive
#56

James, I’ll begin here, and after that I’ll hand things over to Stefan for the pharma part, of course. So let me share this. For me there are two components when it comes to staying confident about our mid-term outlook. One of those, of course, is the innovation and the launches that sit in our plan. That work keeps moving forward the way we see it today — not just the new blockbusters, but also the engine behind our breeding efforts and everything we’re doing. And this year we’re demonstrating that through the market share gain I mentioned earlier. So one side of that equation is the innovation. The other side of that equation is what we call operational excellence, right? Under the new operating model we have, the organization keeps a strong focus on our triangle that Wolfgang brought up many times here — how we generate more cash, how we expand our margin, and how we grow — and there are plenty of initiatives on that front. Some of them I mentioned earlier to Vincent, such as the work we’re doing in product supply to cut our cost on raw materials, along with many other efforts we’re pursuing under the new system.

Bill Anderson

executive
#57

Additionally, our internal cost—our OpEx, factoring in the fresh savings we've achieved. There's also efficiency we can capture in our cost to serve. That said, with the investment we're making in marketing funding, we recoup that investment through our R&D engine, weighing the trade-offs among products—specifically which products we'll have that month. So if I were to boil these two key elements down: first, obviously, we have this innovation engine, and there are plenty of launches. In 10 years, we're probably launching more products than we would have launched in the 20 years prior. That's one element. But the second element is what we refer to as operational excellence—a great deal of the effort we're putting in place to achieve that. That's the reason we keep at it. Once more, I just want to underscore one point on that. When I say that, I'm starting from the fact that in 2023, as you saw on this slide, and in 2024, we are outperforming the market, and we are outperforming the key competitors. They come from that position to drive the future. And we need to address this regulatory issue in 2025.

Bill Anderson

executive
#58

Okay, Stefan, over to you.

Stefan Oelrich

executive
#59

Okay, thanks James for that question. So at the time we issued guidance, we anticipated there would be at-risk launches from generics competing against a patent we still consider strong as of today. And during the third quarter we saw that accelerate. Q3 came in at -23% for Xarelto, against a year-to-date figure of -11%. That trend, then, should be expected to carry on. So treat the third quarter as a signal of what next year likely holds. That said, things can shift, and it depends on generic manufacturers deciding whether to launch at risk against us. So it's partly something we don't control. Still, I believe that gives you a reasonable steer. Excellent. Many thanks. Next up we have Christian Faitz from Kepler Cheuvreux. Christian?

Christian Faitz

analyst
#60

Yes, thank you. I hope you’re able to hear me. Good afternoon, everyone. Good morning, everyone. I’ve got no further questions about 2025 on my end. As for everything else in crop in 2025, we can only hope, pray, do a rain dance, and so on. But regarding FX, may I ask which factors were the main negative drags on FX in crop during Q3? Was Argentina the cause? And if that’s the case, how does Q4 look from an FX perspective for crop? And perhaps also offer us a peek at 2025 purely in FX terms. Thanks. Yeah, hello, Christian.

Bill Anderson

executive
#61

Appreciate the FX question. I really believe the main driver in 2025 is coming from Brazil, Argentina, and other economies with hyperinflation like Turkey and Russia, among others. You've seen us nudge the revenue guidance a bit. On the EPS side, we held it at roughly €0.30 of impact versus last year's currencies. At the close of September, the dollar stood fairly weak at 112. So you picked up the compensating gain on our net financial debt. None of us has a crystal ball. Our usual approach is to examine the eight-month or nine-month forwards to get a read on what lies ahead. That's exactly what we did for Q4, which is why we gave that guidance. And for 2025, we're likewise steering by the forward rates. That's the most we can do. Obviously, you should presume that every hedging tool available is something we employ, and we do so fairly effectively. So expect more updates once we're into the new year.

Christian Faitz

analyst
#62

All right, thank you so much.

Bill Anderson

executive
#63

Thanks, Christian.

Jost Reinhard

executive
#64

Thank you. Next in line, we have Richard Vosser of JP Morgan. Richard?

Richard Vosser

analyst
#65

Thank you. I appreciate you taking my questions. So possibly a question about corn. From what I understand, early signals out of the U.S. point to acreage falling once more. So I'm curious as to when we might expect some relief there, and what the true fundamental factors are that could genuinely turn that area around. And then perhaps a second question, also regarding the crop business — specifically the crop protection business as a whole. Just your thinking on volume and price given the effect of generic pressure. Any additional detail you can provide on that would be quite useful. Thank you so much.

Bill Anderson

executive
#66

Thanks, Richard. And it's quite notable what we witnessed this year — the effect in North America with the four million acres we have, and then the combined effect from Europe and Latin America, both Argentina and Brazil, correct? The signal you just gave regarding next season stems from the fact that the U.S. is having a very high-yielding season, right? A few of you — Joel, I believe you wrote about that — noted the high-yield season in the U.S. and how it's affecting the market. When a shift might appear there is tough to predict. I'm watching the market very closely, because given the impact we're seeing in Argentina — in Argentina, we're talking about a 15%-20% area reduction in corn. We're seeing a 5%-10% reduction in the summer Brazil, and we're going to see the impact in the safrinha as well. So over the next months we're going to watch the balance between corn supply and demand very closely right now. But because of supply and global corn demand, we'll probably see a bit of a shift coming from this corn impact, right? I believe we could see a recovery of that in the second half of next year.

Bill Anderson

executive
#67

Regarding CP, you gave a bit of detail on that, correct? So there's the general pressure in the market, which isn't new, but it has kept having an effect, as you've heard from every company. We touched on that briefly. If you look at our figures, volume continues as we planned. Pricing is affected. The primary effect of the generics, I'd say, is the pricing part of it. And that's what we're tackling. It also ties to the question Vincent asked me earlier. Our action is how we cut cost, how we go very aggressively into raw material negotiations, how we turn efficiency at our sites into lower cost, of course, to maximize that. At the same time, bringing new formulations to market to deliver innovation that lets us have a price advantage here. So that's the engine we're putting in place. And of course, evaluating the CP business each time. This is something we do annually. We evaluate our products, examine the margin of each active ingredient we have, and make changes as needed.

Bill Anderson

executive
#68

That's essentially the effect we're seeing on CP worldwide, though as you mentioned, Richard, it's mostly on pricing. Thanks, Richard.

Jost Reinhard

executive
#69

Great. Next up we have Laurent Favre with BNP. Laurent, go ahead.

Laurent Favre

analyst
#70

Good afternoon, everyone. My first question is for Rodrigo, and I apologize for pressing you a bit further on the deflation expected next year in both seeds, cogs, and CP. Given what your peers have been saying, it seems logical to assume you could bring in roughly EUR 500 million of lower cost next year between seeds and CPC. Is there any reason those figures wouldn't apply to Bayer—for example, your hedging policy? That's the first question. The second one is for Wolfgang, on the free cash flow side: it seems that this year, most of the free cash flow improvement really comes from litigation and incentives payouts. I'm wondering what you can say about working capital, and whether the controllable working capital improvement is more of a 2025 story, or should we be assuming that it's helpful for Q4 in order to reach your free cash flow target? Thank you.

Rodrigo Santos

executive
#71

Okay, Wolfgang, I’ll begin there and then hand it back to you on that point. So again, just as Wolfgang mentioned, today I realize you’ll be hearing somewhat more about 2025. At Bayer, we aren’t giving guidance for 2025, but we do—we’re doing a great deal of work on cost reduction, and we expect meaningful cost reduction next year in our CP, raw material impact, and some other actions we’re putting in place. I won’t be able to tell you the size of those savings that we’re putting in place. You also heard a bit from Wolfgang about the savings we’re delivering through a new operating model, and that will continue next year, along with some other actions we’re putting in place. I’ll need some time to finalize that work and give you a more precise number. But yes, we do see the same savings you’ve heard from other companies. We’re also seeing that cost reduction in our plans, a reduction in terms of our efficiency in our operating model as well. And we’ll provide that number on the next quarter earnings call.

Rodrigo Santos

executive
#72

Wolfgang?

Bill Anderson

executive
#73

Yeah, Laurent, thanks for asking about free cash flow. Clearly, that's top of mind. You're right. Two of the biggest year-over-year effects are lower settlements and lower incentive payouts. You can see that especially in the first nine months. As I said on the call, we stood at -€200 million this year. The year before, we were at -€2.9 billion. We're already seeing some impact on inventory. If you look at it across the year, that's down. We always count on Q4 to see how receivables are going. There's always a payment pattern, particularly in crop, that will determine how we come in and what sort of use we make of programs like factoring. I think we're on the right track there. Our VAT, our weighted average terms with suppliers are improving. So it depends a little bit on what we order when, but the VATs are improving. And then we have laser focus on CapEx as well. So we're addressing all of them. Most impact right now on inventory. Stay tuned on all of the rest. The other thing that obviously is a bit of a burden this year is the lower profitability actually makes a starting point for the free cash flow calculation also a little bit tougher.

Bill Anderson

executive
#74

Even so, we are fully committed to it. We are actively pushing it forward. You can count on an intense, unwavering focus on it.

Jost Reinhard

executive
#75

Alright, thanks. We’re quite short on time now, but there are still five people waiting in the queue, and I’d like to extend them the courtesy of asking their questions. So perhaps those five who are waiting could each ask just one question? We’ll begin with Harry Sephton from UBS.

Harry Sephton

analyst
#76

Great, thanks Jost. My sole question concerns how uptake of high-dose Eylea is progressing. Are the patients you're mostly seeing switches from people already on Eylea, or are they largely new starts being put on high-dose Eylea? And perhaps, tying that together with biosimilars set to launch during the second half of 2025, how defensible would you say the Eylea market is? Thank you.

Wolfgang Nickl

executive
#77

Thanks, Harry. So I'll give you a couple of quick responses. First, yes — what we're predominantly seeing is new starts rather than switches. That doesn't surprise us. And then you ought to consider the analogs within this segment: when it comes to biosimilar penetration, it's been quite modest. So once biosimilars enter the market, we expect switches to come under more pressure. Until that happens, though, I believe new starts will remain the focus. Also keep in mind, when we think about Eylea in Europe, we have a very favorable label there, plus the prefilled syringe that's now becoming available. So that will certainly provide us with extra momentum. Thank you.

Jost Reinhard

executive
#78

Excellent.

Harry Sephton

analyst
#79

Thank you.

Jost Reinhard

executive
#80

Great. Next up we have Sebastian Bray with Berenberg. Sebastian?

Sebastian Bray

analyst
#81

Hi there, hi there. Good afternoon, and I appreciate you taking my question. It concerns what kind of impairment this is in the ag business. From what I remember, the previous impairment was tied specifically to the cotton piece of ag demand. Could you discuss which parts exactly were impaired inside the ag segment and which assumptions, in quantitative terms, would have been different? And if I may fit a second one in, what number of glyphosate cases remain outstanding in the U.S.? Thank you.

Wolfgang Nickl

executive
#82

Sure, I can cover both of those. Hi there, Sebastian. To start with the first item: the €3.8 billion impairment broke down as €3.3 billion at the goodwill level and €0.5 billion for a cash generating unit. As I believe I said, the drivers were generic pricing in crop protection, registrations, and FX. The CGU — the cash generating units — was cotton, which also hinges on the dicamba registration. As for open cases, I believe the count stands at 63,000, though that comes as no surprise. The same parties keep filing additional cases with us each month, essentially to ramp up the pressure. We feel quite confident given 114 of the last 21 cases, and with the circuit split Bill referenced, we're pressing ahead. Thank you, Sebastian.

Sebastian Bray

analyst
#83

I appreciate that.

Wolfgang Nickl

executive
#84

Glad to have you with us.

Jost Reinhard

executive
#85

Up next, we have Thibault Boutherin from Morgan Stanley.

Thibault Boutherin

analyst
#86

Thanks a lot. I just have a question about the US Supreme Court review, given the circuit split. If you could clarify: your slide seems to suggest that you hold the initiative over which case you want to bring to the US Supreme Court. So I just want to confirm that this is the case — that the initiative is in your hands — and that it isn't a situation where you'd need to lose another case in the appeal court in order to be able to go to Supreme Court.

Bill Anderson

executive
#87

It's a bit complicated, honestly, since multiple scenarios exist. We have several cases we might decide to appeal; certain ones have already gone through all appeals, while others remain under appeal. Beyond that, the plaintiffs might also file an appeal regarding the Third Circuit Court ruling. So a range of different scenarios is in play. And honestly, we'd be fairly pleased with whichever one of those outcomes occurs, and at the moment we're essentially trying to optimize around that.

Jost Reinhard

executive
#88

Great. There are two additional questions still in the queue. We really appreciate your patience. The first comes from Stephen Byrne at Bank of America. Stephen?

Steve Byrne

analyst
#89

Yes, thank you. I just wanted to ask a bit about the short stature corn, and maybe beyond the lower lodging risk that Bill brought up—Rodrigo, could you speak to a couple of things? The average increase in planting density, the average yield, and those would be measured against comparable genetics in the same region, plus any estimate on drought tolerance: given the structural change in the plant, is there a drought tolerance element here, which was what drove food inflation?

Wolfgang Nickl

executive
#90

Hi, Steven, and thank you for that question. So, during the second week of January, we will once again be getting together with the Ground Breakers here in the U.S., close to one of our sites. We are going to embark on another season of collaboration with them. And what we are observing among them is precisely what you described. A crucial factor in achieving yield gains at this point is greater plant density, correct? Given all the precision breeding efforts we are undertaking, we are breeding for greater plant density. And naturally, short stature corn enables us to deliver that factor — not merely greater density, but variable seed rating within the acre too. And I believe that represents the primary driver behind the higher yield we are pursuing here. That is precisely what we observed among the Ground Breakers during the last season, and it is precisely what we are also pursuing for the upcoming round with the breeding version that Bill referenced, which Bill was harvesting here in Iowa not long ago. But regarding the second factor you mentioned, we are carrying out that analysis at this very moment, correct? We clearly observed a greater volume of roots emerging from the short stature corn, correct?

Wolfgang Nickl

executive
#91

Since our root development is stronger, we're also grasping what that means for drought tolerance, for stability, and even for a side effect involving carbon sequestration. So that's something we're addressing in the upcoming round of Ground Breakers. We'll be sitting down with the farmers in January, and we're just as enthusiastic about the progress as they are. But you hit the nail on the head, Steve. A crucial part of this is driving greater density so farmers can achieve bigger yields, and that's a highly significant piece of the plan here. Bill, would you like to weigh in on anything, Bill, based on what you've seen?

Bill Anderson

executive
#92

I believe you’ve addressed nearly all of it. The one thing left to mention is what we’re finding in Italy — namely, that the breeding version at least appears to offer better characteristics when used as silage, given the plant’s composition and its lower lignin content. So yes, it’s more nutritious for dairy herds and results in less methane production. So yes, we’re quite enthusiastic about Preceon and what lies ahead. The final question today comes from Tony Jones at Redburn Atlantic. Tony. Tony, are you still with us? If you’re not, then I suppose we’ll wrap up our Q&A session for today. We’ll bring our conference call to a close. Many thanks for your attention and patience, and for your interest, and I hope you all have a wonderful day ahead. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.